Liver Cancer and Metastases

  • Christine F. Lauro
  • Tracey E. Schefter
Part of the Medical Radiology book series (MEDRAD)


The treatment of hepatocellular carcinoma and liver metastases pose unique considerations to the radiation oncologist. The increasing incidence of hepatocellular carcinoma in North America mandates the refinement of prevention strategies, identification of high-risk individuals, and further development of prognostic and predictive scoring systems for locally ablative therapies. Given the advances in systemic therapy for patients with colorectal malignancies, as well as for other primaries, there is a subset of patients who can experience a prolonged disease-free interval or are potentially curable from the ablation of metastatic liver lesions. More refined methods for identifying these patients using clinical and pathologic factors are currently under investigation. With the advent of conformal radiotherapy and stereotactic radiotherapy, there is a low risk of hepatic toxicity for patients with normal hepatic function. Caution should be exercised when treating patients with underlying hepatic compromise.


Hepatocellular Carcinoma Portal Vein Thrombosis Stereotactic Body Radiation Therapy Conformal Radiotherapy Primary Liver Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Hepatocellular carcinoma


Radiation-induced veno-occlusive liver disease


Stereotactic body radiation therapy




  1. Abdalla E (2009) Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg 197:737–739PubMedGoogle Scholar
  2. Abrams R, Pajak T et al (1998) Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 4:178–184PubMedGoogle Scholar
  3. Adam R, Azoulay D et al (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238:508–519PubMedCentralPubMedGoogle Scholar
  4. Alberts S, Horvath W et al (2005) Oxaliplatin, flurouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243–9249PubMedGoogle Scholar
  5. Aloia T, Vauthey J et al (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–467PubMedGoogle Scholar
  6. Beasley R, Hwang L et al (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2:1129–1133PubMedGoogle Scholar
  7. Ben-Josef E, Normolle D et al (2005) Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23:8739–8747PubMedGoogle Scholar
  8. Bengmark S, Hafstrom L (1969) The natural history of primary and secondary tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparatomy. Cancer 23:198–202PubMedGoogle Scholar
  9. Benson A, Abrams T et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391PubMedGoogle Scholar
  10. Benvegnu L, Alberti A (1996) Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 41:S49–S55Google Scholar
  11. Blomgren H, Lax I et al (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol 34:861–870PubMedGoogle Scholar
  12. Bongers E, Haasbeek C et al (2011) Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol 6:252–257Google Scholar
  13. Borgelt B, Gelber R et al (1981) The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. J Radiat Oncol Biol Phys 7:587–591Google Scholar
  14. Bosch F, Ribes J et al (2004) Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:S5–S16PubMedGoogle Scholar
  15. Brock K (2011) Imaging and image-guided radiation therapy in liver cancer. Semin Radiat Oncol 21:247–255PubMedCentralPubMedGoogle Scholar
  16. Bruix J, Castells A et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1022PubMedGoogle Scholar
  17. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022PubMedCentralPubMedGoogle Scholar
  18. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedGoogle Scholar
  19. Cance W, Stewart A et al (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88:912–920PubMedGoogle Scholar
  20. Cardenes H, Price T et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12:218–225PubMedGoogle Scholar
  21. Cardenes, H., Lasley, F. et al. (2012). Stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma with Child-Pugh class B. J Clin Oncol 30(suppl; abstr) e14683Google Scholar
  22. Chang D, Swaminath A et al (2011) Stereotactic body radiotherapy for colorectal liver metastases. Cancer 117:4060–4069PubMedGoogle Scholar
  23. Chen C, Yu M et al (1997) Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S294–S308PubMedGoogle Scholar
  24. Chen M, Li J et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–328PubMedCentralPubMedGoogle Scholar
  25. Cheng A, Kang Y et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34PubMedGoogle Scholar
  26. Cheng J, Wu J et al (2002) Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54:156–162PubMedGoogle Scholar
  27. Cirocchi, R., Trastulli, S. et al. (2012). Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Datab Syst Rev 6 CD006317Google Scholar
  28. Creach K, El Naqa I et al (2012) Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother Oncol 104:23–27PubMedGoogle Scholar
  29. Daowood O, Mahadevan A et al (2009) Stereotactic body radiation therapy for liver metastases. Eur J Cancer 45:2947–2959Google Scholar
  30. Dawson L, McGinn C et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18:2210–2218PubMedGoogle Scholar
  31. Dawson L, Normolle D et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821PubMedGoogle Scholar
  32. de Jong M, Pulitano C et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440–448PubMedGoogle Scholar
  33. DeLeve L (1998) Glutathione defense in non-parenchymal cells. Semin Liver Dis 18:403–413PubMedGoogle Scholar
  34. Dunlap N, Cai J et al (2010) Chest wall volume receiving >=30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76:796–801PubMedGoogle Scholar
  35. El-Seraq H (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27–S34Google Scholar
  36. Emami B, Brown L et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedGoogle Scholar
  37. Ettinger D, Bepler A (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740–801PubMedGoogle Scholar
  38. Fattovich G, Stroffolini T et al (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50PubMedGoogle Scholar
  39. Fong Y, Fortner J et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCentralPubMedGoogle Scholar
  40. Foster J (1984) Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis 4:170–179PubMedGoogle Scholar
  41. Gençel O, Naziroglu M et al (2010) Selenium and vitamin E modulates radiation-induced liver toxicity in pregnant and nonpregnant rat: effects of colemanite and hematite shielding. Biol Trace Element Res 135:253–263Google Scholar
  42. Gleisner A, Choti M et al (2008) Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-frequency ablation. Arch Surg 143:1204–1212PubMedGoogle Scholar
  43. Goodman K, Wiegner E et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493PubMedGoogle Scholar
  44. Goyal K, Einstein D et al (2010) Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. HPB Surg 309780Google Scholar
  45. Guha C, Kavanagh B (2011) Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 21:256–263PubMedCentralPubMedGoogle Scholar
  46. Hassan M, Hwang LY et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213PubMedGoogle Scholar
  47. Heckman J, Devera M et al (2008) Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 15:3169–3177PubMedGoogle Scholar
  48. Heintges T, Wands J (1997) Hepatitis C virus: epidemiology and transmission. Hepatology 26:521–526PubMedGoogle Scholar
  49. Hendlisz A, van den Eynde M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694PubMedGoogle Scholar
  50. Hepatocellulaire GdEedTdC (1995) A comparison of lipiodol chemoemboliation and conservation treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261Google Scholar
  51. Herfarth K, Debus J et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170PubMedGoogle Scholar
  52. Herfarth K, Hof H et al (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57:444–451PubMedGoogle Scholar
  53. Hoyer M, Roed H et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830PubMedGoogle Scholar
  54. Huang J, Yan L et al (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 252:903–912PubMedGoogle Scholar
  55. Hur H, Ko Y et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736PubMedGoogle Scholar
  56. Ingold J, Kaplan R et al (1965) Radiation hepatitis. AJR Am J Roentgenol 93:200–208Google Scholar
  57. Jemal A, Siegel R et al (2010) Cancer statistics. CA Cancer J Clin 60:277–300PubMedGoogle Scholar
  58. Kanematsu M, Hoshi H et al (1999) Small hepatic nodules in cirrhosis: ultrasonographic, CT, and MR imaging findings. Abdom Imaging 24:47–55PubMedGoogle Scholar
  59. Katz A, Chawla S et al (2012) Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 83:895–900PubMedGoogle Scholar
  60. Kemeny N (2006) Management of liver metastases from colorectal cancer. Oncology 20:1161–1176PubMedGoogle Scholar
  61. Kim T, Kim D et al (2006) Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 29:568–575PubMedGoogle Scholar
  62. Kothary N, Heit J et al (2009) Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. J Vasc Intervent Radiol 20:235–239Google Scholar
  63. Kulik L, van Holsbeeck A et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586PubMedGoogle Scholar
  64. Kwon J, Bae S et al (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475PubMedCentralPubMedGoogle Scholar
  65. Lawrence TS, Robertson JM et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248PubMedGoogle Scholar
  66. Lax I, Blomgren D et al (1998) Extracranial stereotactic radiosurgery of localized targets. J Radiosurg 1:135–148Google Scholar
  67. Lee M, Kim J et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591PubMedGoogle Scholar
  68. Liang SX, Zhu XD et al (2005) Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 103:2181–2188PubMedGoogle Scholar
  69. Liang SX, Zhu XD et al (2006) Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65:426–434PubMedGoogle Scholar
  70. Liebel S, Massullo P et al (1987) A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys 13:1057–1064Google Scholar
  71. Liu MT, Li SH et al (2004) Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Japan J Clin Oncol 34:532–539Google Scholar
  72. Llovet JM, Bruix BA et al (2003) Hepatocellular carcinoma. Lancet 362:1907–1917PubMedGoogle Scholar
  73. Llovet JM, Di Bisceglie AM et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedGoogle Scholar
  74. Llovet J, Ricci S, Mazzaferro V et al (2007) Sharp investigators sorafenib improves survival in advanced hepatocellular carcinoma (hcc): results of a phase III randomized placebo-controlled tria! J Clin Oncol LBA1Google Scholar
  75. Louis C, Dewas S et al (2010) Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 9:479–487PubMedGoogle Scholar
  76. Lu DS, Yu N, Raman S (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130–1137Google Scholar
  77. Mazzaferro V, Doci RE et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMedGoogle Scholar
  78. McGinn CJ, Ensminger T et al (1998) Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 16:2246–2252PubMedGoogle Scholar
  79. Memon K, Lewandowski RJ et al (2011) Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol 21:294–302PubMedCentralPubMedGoogle Scholar
  80. Mendez-Romero A, Wunderink W et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 45:831–837PubMedGoogle Scholar
  81. Mohiuddin M, Ahmad CE et al (1996) Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14:722–728PubMedGoogle Scholar
  82. Mornex F, Girard N et al (2006) Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66:1152–1158PubMedGoogle Scholar
  83. Muratore A, Bouzari ZD et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14:766–770PubMedGoogle Scholar
  84. O’Connor JK, Davis TJ et al (2012) Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 18:949–954PubMedGoogle Scholar
  85. Okuda K, Obata OT et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedGoogle Scholar
  86. Parkin DM, Ferlay BF et al (2001) Estimating the world cancer burder: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedGoogle Scholar
  87. Pawlik T, Scoggins C et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–724PubMedCentralPubMedGoogle Scholar
  88. Pelletier G, Ink RA et al (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184PubMedGoogle Scholar
  89. Penna C (2002) Colorectal metastasis (liver and lung). Surg Clin N Am 82:1075–1090PubMedGoogle Scholar
  90. Poon R, Lau C et al (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835–1845PubMedGoogle Scholar
  91. Prasad B, Hendrickson LM et al (1977) Irradiation of hepatic metastases. Int J Radiat Oncol Biol Phys 2:129–132PubMedGoogle Scholar
  92. Reed GB (1966) The human liver after radiation injury. Am J Pathol 48:597–611PubMedCentralPubMedGoogle Scholar
  93. Reuter NP, Scoggins WC et al (2009) Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 13:486–491PubMedGoogle Scholar
  94. Ries L, Kosary EM et al (2004) SEER Cancer statistics review, 1975–2001. National Cancer Institute, BethesdaGoogle Scholar
  95. Robertson JM, Walker LT et al (1995) The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys 32:445–450PubMedGoogle Scholar
  96. Robertson JM, Walker M et al (1997) A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 39:1087–1092PubMedGoogle Scholar
  97. Rule W, Timmerman R et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:1081–1087PubMedGoogle Scholar
  98. Russell AH, Wasserman CC et al (1993) Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 27:117–123PubMedGoogle Scholar
  99. Rusthoven K, Kavanagh B et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578PubMedGoogle Scholar
  100. Salem R, Lewandowski RJ et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507PubMedCentralPubMedGoogle Scholar
  101. Schefter TE, Kavanagh BD et al (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371–1378PubMedGoogle Scholar
  102. Schefter TE, Kavanagh BD (2011) Radiation therapy for liver metastases. Semin Radiat Oncol 21:264–270PubMedGoogle Scholar
  103. Seo Y, Kim M et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–214PubMedGoogle Scholar
  104. Seong J, Lee I et al (2009) A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 29:147–152PubMedGoogle Scholar
  105. Shah S, Coates BR et al (2007) Survival after liver resection for metastatic colorectal carcinoma in a large population. J Am Coll Surg 205:676–683PubMedGoogle Scholar
  106. Shannon AM, Williams KJ (2008) Antiangiogenics and radiotherapy. J Pharm Pharmacol 60:1029–1036PubMedGoogle Scholar
  107. Sherman DM, Order S (1978) Palliation of hepatic metastasis. Cancer 41:2013–2017PubMedGoogle Scholar
  108. Simmonds P, Primrose J et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 20:982–999Google Scholar
  109. Son SH, Choi BO et al (2010) Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: Dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 78:1073–1080PubMedGoogle Scholar
  110. Spradling P, Rupp L et al (2012) Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 55:1047–1055PubMedGoogle Scholar
  111. Stenmark M, Liu E et al (2011) SBRT outcomes for primary and metastatic liver lesions. ASCO Gastrointestinal Cancers Symposium, San FranciscoGoogle Scholar
  112. Stillwagon GB, Guse OS et al (1989) 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 17:1223–1229PubMedGoogle Scholar
  113. Taniai N, Yoshida H et al (2006) Outcome of surgical treatment of synchronous liver metastases from colorectal cancer. J Nippon Med Sch 73:82–88PubMedGoogle Scholar
  114. Timmerman R, Kavanagh B et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952PubMedGoogle Scholar
  115. Timmerman R, Galvin PR et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076PubMedCentralPubMedGoogle Scholar
  116. Timmerman R, Bizekis C et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA: Cancer J Clinicians 59:145–170Google Scholar
  117. Tomizawa N, Ohwada S et al (2006) Factors affecting prognosis of anatomical liver resection for liver metastases from colorectal cancer. Hepatogastroenterology 53:89–93PubMedGoogle Scholar
  118. Tsai MS, Su YH et al (2007) Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14:786–794PubMedGoogle Scholar
  119. Tse R, Hawkins M et al (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657–664PubMedGoogle Scholar
  120. Van Cutsem E, Adam NB et al (2006) Towards a pan-Europen consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221PubMedGoogle Scholar
  121. Wang X, Zhang K et al (2008) Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 33:259–267PubMedGoogle Scholar
  122. Wei AC, Grant GP et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13:668–676PubMedGoogle Scholar
  123. Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382PubMedGoogle Scholar
  124. Wong S, Mangu P et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508PubMedGoogle Scholar
  125. Woody NM, Videtic GM et al (2012) Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. Int J Radiat Oncol Biol Phys 83:427–434PubMedGoogle Scholar
  126. Xu ZY, Liang SX et al (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195PubMedGoogle Scholar
  127. Zhang BH, Tang YB et al (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of Colorado DenverAuroraUSA

Personalised recommendations